1. Home
  2. ATNM vs NEPH Comparison

ATNM vs NEPH Comparison

Compare ATNM & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.58

Market Cap

50.2M

Sector

Health Care

ML Signal

HOLD

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$4.96

Market Cap

60.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
NEPH
Founded
2000
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.2M
60.0M
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
ATNM
NEPH
Price
$1.58
$4.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$4.00
$6.00
AVG Volume (30 Days)
224.5K
75.2K
Earning Date
11-14-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.14
Revenue
$90,000.00
$17,930,000.00
Revenue This Year
N/A
$33.32
Revenue Next Year
$42,943.57
$12.27
P/E Ratio
N/A
$36.15
Revenue Growth
11.11
32.36
52 Week Low
$1.03
$1.39
52 Week High
$2.41
$6.42

Technical Indicators

Market Signals
Indicator
ATNM
NEPH
Relative Strength Index (RSI) 65.07 47.81
Support Level $1.37 $4.83
Resistance Level $1.54 $5.97
Average True Range (ATR) 0.08 0.62
MACD 0.02 -0.04
Stochastic Oscillator 72.95 26.90

Price Performance

Historical Comparison
ATNM
NEPH

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: